Fresenius Medical Care

FMS

Market cap $11.6B

BAD HOMBURG, Germany, May 28, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the launch of the first tranche of its new share buyback program with a total volume of around EUR 1 billion. The first tranche, amounting up to EUR 600 million, was initiated today and is expected to be completed by December 15, 2026.

Hemodiafiltration (HDF) research reinforces Fresenius Medical Care's continued leadership in advancing evidence-based dialysis care and treatment personalization New research focuses on applying real-world evidence, patient-centered outcomes and artificial intelligence across dialysis modalities and continuity of kidney care A preview of kinexus, a unified digital platform intended to support home dialysis programs by connecting therapy management and care workflows BAD HOMBURG, Germany, May 27, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with kidney diseases, presents new research highlighting ongoing innovation at the European Renal Association (ERA) Congress 2026, June 3-6 in Glasgow, Scotland, and virtually. The Company highlights advancements including new hemodiafiltration research that reaffirm its leadership in evidence based and personalized dialysis care, real-world evidence to strengthen patient centered outcomes across dialysis modalities, and the application of artificial intelligence (AI) to improve patient outcomes.

Total volume of the share buyback is around EUR 1 billion over 12 months Share buyback expected to begin in the near future BAD HOMBURG, Germany, May 26, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, intends to execute a new share buyback program with a total volume of around EUR 1 billion. The program shall be executed in tranches over a period of 12 months from its start.

Shareholders approve proposed dividend of EUR 1.49 per share FME Reignite strategy launched in 2025 successfully drives the next phase of value creation 5008X CAREsystem introduced in U.S. clinics; full U.S. commercial launch underway in 2026 EUR 1 billion share buyback program successfully completed, and a new authorization granted to support the Company's capital allocation framework which includes share buyback programs BAD HOMBURG, Germany, May 21, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has completed a milestone year marked by significant improvements in profitability. Over the past three years, the Company has successfully delivered on its mid‑term financial and strategic targets set for 2025.

BAD HOMBURG, Germany, May 20, 2026 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care AG, the world's leading provider of products and services for individuals with renal disease, today has reappointed Chief Financial Officer (CFO) and Management Board Member Martin Fischer (49) for a period of five years until 2031. Michael Sen, Chairman of the Supervisory Board, commented, "Martin Fischer has demonstrated strong and consistent leadership and has further strengthened Fresenius Medical Care's governance, transparency, and financial discipline.

Valvoline was Broyhill's largest contributor in the quarter, as the underlying unit economics are intact, while unit growth, service mix, and price continue moving in the same direction. Honeywell management accelerated the aerospace spin-off to the end of June, leaving behind a pure-play automation business that Broyhill believes is worth meaningfully more than the whole. Large pharma is structurally reliant on IQVIA's clinical trial architecture and proprietary data assets, and Broyhill thinks it is highly unlikely that AI can automate away the FDA approval process.

Fresenius Medical's shares rise after Q1 earnings miss estimates as margin expansion and FME25+ savings support operating income growth.

Fresenius Medical Care AG (FMS) Q1 2026 Earnings Call Transcript

Fresenius Medical Care is undervalued at a sub-10x P/E despite 7-9% AEPS growth and improved fundamentals. FMS has achieved 300-400 bps margin expansion, €800M+ in savings, and reduced leverage to 2.5x, supporting a more robust investment-grade profile. Even with flat or low growth, FMS offers 40-60% multi-year upside to a $29/share price target, justifying a 'Buy' rating.

Organic revenue growth1 of 4% with growth in all operating segments Operating income2 grew 10%, resulting in further margin expansion to 10.1% FME25+ transformation program related one-time costs mainly drove reported operating income decline of 14% and reported net income3 decrease of 22% Earnings per share2 (EPS) increased by 16%, supported by the share buyback program FY 2026 outlook confirmed BAD HOMBURG, Germany, May 5, 2026 /PRNewswire/ -- "Fresenius Medical Care delivered continued operational and financial progress in the first quarter, with organic revenue growth, improved profitability and adjusted EPS growth. Operating income growth was in line with our planned phasing," said Helen Giza, Chief Executive Officer of Fresenius Medical Care.